Harry Kleanthous

Corporate Officer/Principal bei SK BIOSCIENCE CO.,LTD.

Health Technology

Consumer Services

Profil

Harry Kleanthous is currently working as Vice President-Research at Acambis Plc and EVP-Vaccine Research & Development Strategy at SK bioscience Co., Ltd.
He holds a doctorate degree from the University of London.

Aktive Positionen von Harry Kleanthous

Unternehmen	Position	Beginn
SK BIOSCIENCE CO.,LTD.	Corporate Officer/Principal	21.10.2022
Acambis Plc Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK.	Corporate Officer/Principal	-

Alle aktiven Positionen von Harry Kleanthous

Ausbildung von Harry Kleanthous

University of London

Doctorate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Harry Kleanthous im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	1
SK BIOSCIENCE CO.,LTD.	Health Technology

Private Unternehmen	1
Acambis Plc Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK.	Health Technology